Physician profile
Samer Charbel
NPI 1144499468
$4,951.45
in general payments reported to CMS, 2019-2025
30 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $166 · 2021: $261 · 2022: $1,236 · 2023: $1,339 · 2024: $569 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.55 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.26 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pentax of America, INC. | $500.00 | 2023 | |
| Genzyme Corporation | $453.72 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $359.00 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $356.72 | 2019-2025 | Entyvio |
| Cook Medical LLC | $224.22 | 2022 | |
| Qol Medical, LLC | $175.04 | 2022-2023 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.37 | 2019-2023 | Xifaxan |
| Celgene Corporation | $148.41 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $135.21 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $133.34 | 2022-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $120.10 | 2022 | |
| Janssen Biotech, INC. | $106.89 | 2020-2024 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $103.75 | 2022 | |
| Boston Scientific Corporation | $79.29 | 2022-2024 | Spyglass |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $75.12 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $69.31 | 2019-2024 | Sutab, Suflave |
| Olympus America INC. | $65.48 | 2023 | Visiglide |
| Gilead Sciences, INC. | $64.94 | 2022-2025 | |
| Celltrion USA INC. | $55.76 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $50.36 | 2019-2023 | Dificid |
| Pfizer INC. | $49.86 | 2019-2025 | |
| Conmed Corporation | $37.72 | 2021 | |
| Daiichi Sankyo INC. | $30.95 | 2019 | |
| Allergan, INC. | $25.89 | 2019 | |
| Endo Pharmaceuticals INC. | $24.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.11 | 2023 | Cyltezo |
| Novo Nordisk INC | $19.08 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $18.69 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Charbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.